TERN | Terns Pharmaceuticals, Inc.

Index- P/E- EPS (ttm)-1.58 Insider Own2.10% Shs Outstand69.78M Perf Week2.38%
Market Cap809.42M Forward P/E- EPS next Y-1.42 Insider Trans122.19% Shs Float35.95M Perf Month-10.08%
Income-68.10M PEG- EPS next Q-0.34 Inst Own98.20% Short Float / Ratio8.27% / 6.84 Perf Quarter13.84%
Sales- P/S- EPS this Y24.20% Inst Trans29.46% Short Interest2.97M Perf Half Y49.29%
Book/sh4.12 P/B2.82 EPS next Y-4.40% ROA-29.40% Target Price17.17 Perf Year598.80%
Cash/sh4.26 P/C2.72 EPS next 5Y- ROE-30.80% 52W Range1.60 - 14.04 Perf YTD13.95%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-17.40% Beta-
Dividend %- Quick Ratio24.70 Sales past 5Y- Gross Margin- 52W Low625.00% ATR0.93
Employees46 Current Ratio24.70 Sales Q/Q- Oper. Margin- RSI (14)50.76 Volatility8.32% 8.41%
OptionableYes Debt/Eq0.00 EPS Q/Q43.40% Profit Margin- Rel Volume0.87 Prev Close11.30
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume434.34K Price11.60
Recom2.20 SMA20-0.11% SMA50-0.96% SMA20038.28% Volume375,761 Change2.65%
Date Action Analyst Rating Change Price Target Change
May-31-23Initiated ROTH MKM Buy $23
May-08-23Initiated BMO Capital Markets Outperform $18
Feb-14-23Initiated JMP Securities Mkt Outperform $17
Feb-07-23Initiated UBS Buy $19
Sep-12-22Initiated H.C. Wainwright Neutral $6
Sep-14-21Resumed Goldman Buy $21
Mar-02-21Initiated JP Morgan Overweight $32
Mar-02-21Initiated Goldman Buy $29
Mar-02-21Initiated Cowen Outperform
Jun-02-23 04:05PM
May-28-23 09:45AM
May-25-23 05:05PM
May-24-23 04:05PM
May-22-23 04:05PM
08:05AM Loading…
May-15-23 08:05AM
May-09-23 04:05PM
May-03-23 04:05PM
Apr-25-23 12:00PM
Mar-30-23 02:28PM
Mar-27-23 04:05PM
Mar-08-23 05:26AM
Mar-02-23 04:05PM
Feb-26-23 10:51AM
12:00PM Loading…
Feb-08-23 12:00PM
Feb-02-23 04:05PM
Jan-12-23 04:05PM
Jan-05-23 04:05PM
Dec-23-22 04:05PM
Dec-20-22 07:40PM
Dec-19-22 04:31PM
Dec-01-22 04:05PM
Nov-16-22 09:31AM
Nov-09-22 04:05PM
Nov-04-22 08:05AM
Oct-26-22 04:05PM
Oct-12-22 05:26AM
Oct-11-22 04:05PM
06:03AM Loading…
Sep-29-22 06:03AM
Sep-21-22 05:33AM
Sep-07-22 04:05PM
Aug-19-22 06:50AM
Aug-12-22 08:00AM
Aug-08-22 04:05PM
Jul-27-22 04:05PM
Jul-22-22 12:00PM
Jun-22-22 04:05PM
Jun-09-22 06:31AM
Jun-08-22 04:05PM
Jun-01-22 04:05PM
May-16-22 04:05PM
Apr-05-22 01:38PM
Apr-04-22 04:05PM
Mar-21-22 04:05PM
Mar-03-22 04:05PM
Feb-28-22 04:05PM
Feb-04-22 11:37AM
Feb-02-22 05:38PM
Jan-06-22 07:05AM
Jan-03-22 04:05PM
Nov-15-21 04:05PM
Nov-12-21 07:05AM
Nov-10-21 07:17AM
Nov-09-21 04:05PM
Nov-03-21 02:52PM
Oct-18-21 04:05PM
Oct-05-21 04:05PM
Oct-04-21 08:38AM
Sep-28-21 04:05PM
Sep-15-21 06:07PM
Sep-08-21 07:05AM
Sep-02-21 04:05PM
Aug-16-21 04:05PM
Aug-03-21 04:05PM
Jun-24-21 04:05PM
Jun-14-21 12:41PM
Jun-13-21 05:00PM
May-19-21 05:00PM
May-13-21 04:05PM
May-06-21 08:59AM
Apr-07-21 07:05AM
Mar-30-21 04:05PM
Mar-26-21 07:31AM
Mar-22-21 07:35AM
Mar-08-21 07:00AM
Mar-01-21 03:20PM
Feb-23-21 04:35PM
Feb-14-21 06:01AM
Feb-12-21 10:58AM
Feb-11-21 08:30AM
Feb-10-21 07:05AM
Feb-09-21 09:00AM
Feb-08-21 09:18AM
Feb-04-21 06:54PM
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lu HongboDirectorDec 23Buy7.25758,6205,499,9954,340,212Dec 23 05:44 PM
Vivo Opportunity, LLC10% OwnerDec 23Buy7.25758,6205,499,9954,340,212Dec 23 05:48 PM
ORBIMED ADVISORS LLCDirectorDec 23Buy7.25137,9311,000,0004,882,854Dec 28 05:57 PM
GORDON CARL LDirectorDec 23Buy7.25137,9311,000,0004,882,854Dec 28 05:46 PM
LAV Biosciences Fund V, L.P.10% OwnerNov 23Sale5.501,500,0008,250,000405,583Nov 28 04:56 PM
Lu HongboDirectorSep 07Buy3.60600,0002,160,0003,581,592Sep 08 08:00 PM
Vivo Opportunity, LLC10% OwnerSep 07Buy3.60600,0002,160,0003,581,592Sep 08 08:00 PM
ORBIMED ADVISORS LLCDirectorAug 16Buy2.423,690,0008,929,8004,744,923Aug 18 05:00 PM
GORDON CARL LDirectorAug 16Buy2.423,690,0008,929,8004,744,923Aug 18 04:50 PM
Vivo Opportunity, LLC10% OwnerAug 16Buy2.421,500,0003,630,0002,981,592Aug 16 08:44 PM
Lu HongboDirectorAug 16Buy2.421,500,0003,630,0002,981,592Aug 16 08:30 PM
Lu HongboDirectorAug 15Buy2.991,2183,6421,481,592Aug 16 08:30 PM
Vivo Opportunity, LLC10% OwnerAug 15Buy2.991,2183,6421,481,592Aug 16 08:44 PM
Vivo Opportunity, LLC10% OwnerAug 12Buy2.981,123,0213,346,6031,480,374Aug 16 08:44 PM
Lu HongboDirectorAug 12Buy2.981,123,0213,346,6031,480,374Aug 16 08:30 PM